Combining Fluorescent in Situ Hybridization Data with ISS Staging Improves Risk Assessment in Myeloma: an International Myeloma Working Group Collaborative Project

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2012 Oct 4

PMID 23032723

Citations 87

Authors

H Avet-Loiseau

B G M Durie

M Cavo

M Attal

N Gutierrez

J Haessler

H Goldschmidt

R Hajek

J H Lee

O Sezer

B Barlogie

J Crowley

R Fonseca

N Testoni

F Ross

S V Rajkumar

P Sonneveld

J Lahuerta

P Moreau

G MORGAN

Affiliations

Soon will be listed here.

Abstract

The combination of serum β2-microglobulin and albumin levels has been shown to be highly prognostic in myeloma as the International Staging System (ISS). The aim of this study was to assess the independent contributions of ISS stage and cytogenetic abnormalities in predicting outcomes. A retrospective analysis of international studies looking at both ISS and cytogenetic abnormalities was performed in order to assess the potential role of combining ISS stage and cytogenetics to predict survival. This international effort used the International Myeloma Working Group database of 12 137 patients treated worldwide for myeloma at diagnosis, of whom 2309 had cytogenetic studies and 5387 had analyses by fluorescent in situ hybridization (iFISH). Comprehensive analyses used 2642 patients with sufficient iFISH data available. Using the comprehensive iFISH data, combining both t(4;14) and deletion (17p), along with ISS stage, significantly improved the prognostic assessment in terms of progression-free survival and overall survival. The additional impact of patient age and use of high-dose therapy was also demonstrated. In conclusion, the combination of iFISH data with ISS staging significantly improves risk assessment in myeloma.

Citing Articles

Is t(11;14) in newly diagnosed multiple myeloma a favorable outcome in the novel agent era?.

Li Y, Deng J, Jian Y, Zhang Z, Chen W Blood Res. 2025; 60(1):11.

PMID: 39913013 PMC: 11802943. DOI: 10.1007/s44313-025-00056-8.

Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation.

Hummel M, Hielscher T, Emde-Rajaratnam M, Salwender H, Beck S, Scheid C JCO Precis Oncol. 2024; 8:e2300613.

PMID: 38986047 PMC: 11371111. DOI: 10.1200/PO.23.00613.

Identifying high-risk multiple myeloma patients: A novel approach using a clonal gene signature.

Li J, Wang C, Cheng C Int J Cancer. 2024; 155(9):1684-1695.

PMID: 38874435 PMC: 11537842. DOI: 10.1002/ijc.35057.

Cytogenetic abnormalities correlate with clinico-biological characteristics in 30 Moroccan multiple myeloma patients.

Hamdaoui H, Nouadi B, Benlarroubia O, Chbel F, Saadoune C, Bennis F Leuk Res Rep. 2023; 20:100392.

PMID: 38035181 PMC: 10685041. DOI: 10.1016/j.lrr.2023.100392.

Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling.

Cardona-Benavides I, Misiewicz-Krzeminska I, Rojas E, de Ramon C, Sanz-Solas A, Isidro I Haematologica. 2023; 109(3):877-887.

PMID: 37646661 PMC: 10905080. DOI: 10.3324/haematol.2023.283445.

References

Gertz M, Lacy M, Dispenzieri A, Greipp P, Litzow M, Henderson K . Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005; 106(8):2837-40. PMC: 1895302. DOI: 10.1182/blood-2005-04-1411. View

Greipp P, San Miguel J, Durie B, Crowley J, Barlogie B, Blade J . International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15):3412-20. DOI: 10.1200/JCO.2005.04.242. View

Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau J . Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002; 100(5):1579-83. DOI: 10.1182/blood-2002-03-0749. View

Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C . Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007; 109(8):3489-95. DOI: 10.1182/blood-2006-08-040410. View

Avet-Loiseau H, Li C, Magrangeas F, Gouraud W, Charbonnel C, Harousseau J . Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol. 2009; 27(27):4585-90. PMC: 2754906. DOI: 10.1200/JCO.2008.20.6136. View

Bataille R, Durie B, Grenier J . Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol. 1983; 55(3):439-47. DOI: 10.1111/j.1365-2141.1983.tb02158.x. View

Chng W, Kuehl W, Bergsagel P, Fonseca R . Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. Leukemia. 2007; 22(2):459-61. DOI: 10.1038/sj.leu.2404934. View

Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A . Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica. 2010; 95(7):1150-7. PMC: 2895040. DOI: 10.3324/haematol.2009.016436. View

Bataille R, Boccadoro M, Klein B, Durie B, Pileri A . C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood. 1992; 80(3):733-7. View

10.

Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50(3):163-70. View

11.

Shaughnessy Jr J, Zhan F, Burington B, Huang Y, Colla S, Hanamura I . A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2006; 109(6):2276-84. DOI: 10.1182/blood-2006-07-038430. View

12.

Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M . Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001; 97(6):1566-71. DOI: 10.1182/blood.v97.6.1566. View

13.

Durie B, Salmon S, MOON T . Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood. 1980; 55(3):364-72. View

14.

Fonseca R, Blood E, Rue M, Harrington D, Oken M, Kyle R . Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003; 101(11):4569-75. DOI: 10.1182/blood-2002-10-3017. View

15.

Jaksic W, Trudel S, Chang H, Trieu Y, Qi X, Mikhael J . Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol. 2005; 23(28):7069-73. DOI: 10.1200/JCO.2005.17.129. View

16.

Kapoor P, Fonseca R, Rajkumar S, Sinha S, Gertz M, Stewart A . Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc. 2010; 85(6):532-7. PMC: 2878257. DOI: 10.4065/mcp.2009.0677. View

17.

Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P . Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du.... J Clin Oncol. 2008; 26(29):4798-805. DOI: 10.1200/JCO.2007.13.8545. View

18.

Bataille R, Durie B, Grenier J, Sany J . Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol. 1986; 4(1):80-7. DOI: 10.1200/JCO.1986.4.1.80. View

19.

Greipp P, Leong T, Bennett J, Gaillard J, Klein B, Stewart J . Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998; 91(7):2501-7. View

20.

Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E . Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000; 95(6):1925-30. View